HIV targets CD62L on central memory T cells through viral envelope glycans for adhesion and induces selectin shedding for viral release

Despite the success of anti-retroviral therapy in controlling HIV in infected individuals, treatment is less effective at eliminating HIV viral reservoirs. The nature of HIV reservoirs and the factors controlling their size and release are a major research focus for achieving a cure for HIV/AIDS.

NIAID researchers have identified L-selectin/CD62L as a new target for treating HIV by inhibiting viral release from infected cells. They found that shedding of CD62L on T cells is required for the efficient release of HIV virus from infected cells. Further, they have shown that inhibition of CD62L shedding dramatically reduced HIV-1 infection and viral release from both viremic and aviremic CD4+ T cells. Therefore, inhibitors for CD62L sheddase can function as an anti-HIV treatment that may be effective alone or in combination with existing therapeutics.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications: Competitive Advantages:
  • New target for HIV therapeutic development.
  • This invention comprises a method of treating HIV using therapeutics geared toward viral release and entry, distinguishing it from other antiviral candidates with its method of action.
  • CD62L is a new target for HIV


Peter Sun (NIAID)  ➽ more inventions...

Joseph Konochik (NIAID)  ➽ more inventions...

Joanna Ireland (NIAID)  ➽ more inventions...

Intellectual Property:
US Application No. 16/065,854
US Application No. 62/271,726
PCT Application No. PCT/US2016/068713

Collaboration Opportunity:

The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further co-develop this technology by identifying pharmacological compounds inhibiting CD62L shedding by using high throughput compound screening. For collaboration opportunities, please contact Chris Kornak at chris.kornak@nih.govor 1-240-627-3705.

Licensing Contact:
Christopher Kornak, J.D.
Phone: 240-627-3705

OTT Reference No: E-261-2015-0
Updated: Jul 31, 2019